PreprintCited by 478Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Research Studies

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Open access

Politi, Katerina, Zakowski, Maureen F., Fan, Pang-Dian, Schonfeld, Emily A., Pao, William, Varmus, Harold E.·2006·Genes & Development

DOI 10.1101/gad.1417406

Open this paper in CoChat — free account Open PDF

Abstract

Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor ( EGFR ) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant ( EGFR Δ L747–S752 ) or the L858R mutant ( EGFR L858R ) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR L858R allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR Δ L747–S752 develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1417406

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D. G., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,229
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Show all 50 references

Sorted by citations

Items 301–400 of 476

FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
Tomoshige, K., Stuart, W. D., Fink-Baldauf, I. M., Ito, M., Tsuchiya, T., Nagayasu, T., Yamatsuji, T., Okada, M., Fukazawa, T., Guo, M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2805 · Cited by 15
Signaling Pathways in Cancer
Kalderon, D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_8 · Cited by 16
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
Akbay, E. A., & Kim, J. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.04 · Cited by 16
Occurrence of mutations in the epidermal growth factor receptor gene in X‐ray‐induced rat lung tumors
Kitahashi, T., Takahashi, M., Yamada, Y., Oghiso, Y., Yokohira, M., Imaida, K., Tsutsumi, M., Takasuka, N., Sügimura, T., & Wakabayashi, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00680.x · Cited by 16
Cancer of the Lung
Horn, L., Eisenberg, R., Gius, D. R., Kimmelshue, K. N., Massion, P. P., Putnam, J. B., Robinson, C. G., & Carbone, D. P. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00072-2 · Cited by 16
Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities
Yousefi, M., Boross, G. Z., Weiss, C. V., Murray, C. W., Hebert, J. D., Cai, H., Ashkin, E. L., Karmakar, S., Andrejka, L., Chen, L. C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0059 · Cited by 15
Targeted Cancer Therapy: Promise and Reality
Klein, S., & Levitzki, A. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97013-4 · Cited by 15
Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone
Kawabata, S., Hollander, M. C., Munasinghe, J., Brinster, L., Mercado-Matos, J., Li, J., Regales, L., Pao, W. J., Janne, P. A., Wong, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3605 · Cited by 15
Self-citation
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non‐small‐cell lung cancer for gefitinib treatment
Jida, M., Toyooka, S., Mitsudomi, T., Takano, T., Matsuo, K., Hotta, K., Tsukuda, K., Kubo, T., Yamamoto, H., Yamane, M., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01273.x · Cited by 15
Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
Dancey, J. E. (2007) · Drugs · doi:10.2165/00003495-200767080-00003 · Cited by 15
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids
Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15
A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer
Tang, X., Cheng, L., Guo, L., Yan, Y., Su, F., Huang, D., Zhang, S., Liu, Z., Qian, M., Li, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02906-4 · Cited by 14
Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
Farnsworth, D., Chen, Y. T., de Rappard-Yuswack, G., & Lockwood, W. W. (2021) · Cells · doi:10.3390/cells10123553 · Cited by 16
Exon 19 of EGFR mutation in relation to the CA‐repeat polymorphism in intron 1
Sueoka‐Aragane, N., Imai, K., Komiya, K., Sato, A., Tomimasu, R., Hisatomi, T., Sakuragi, T., Mitsuoka, M., Hayashi, S., Nakachi, K., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00804.x · Cited by 14
Tetracycline-Regulated Mouse Models of CancerPreprint
Yeh, E. S., Vernon-Grey, A., Martin, H. L., & Chodosh, L. A. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069823 · Cited by 13
ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer
Cui, H., Cai, X.-T., Qian, Q., Fan, S., Li, T. X., Wang, T., Dai, H., Song, Y., Sun, X., & Cao, P. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502778122 · Cited by 13
EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
Hong, S. H., Kang, N., Kim, O., Hong, S. A., Park, J., Kim, J., Lee, M. A., & Kang, J. (2022) · Cancers · doi:10.3390/cancers15010124 · Cited by 14
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy
Bowman, R. L., Dunbar, A. J., Mishra, T., Xiao, W., Waarts, M., Maestre, I. F., Eisman, S. E., Cai, L., Mowla, S., Shah, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.009 · Cited by 14
Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer
Saber, A., van der Wekken, A. J., Kerner, G. S. M. A., van den Berge, M., Timens, W., Schuuring, E. M. D., ter Elst, A., van den Berg, A., Hiltermann, T. J. N., & Groen, H. J. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152317 · Cited by 14
EGFR exon 19 in‐frame deletion and polymorphisms of DNA repair genes in never‐smoking female lung adenocarcinoma patients
Yang, S., Yang, T., Li, Y., Chen, K., Liao, K., Hsu, K.-H., Tsai, C., Chen, C., Hsu, C., Hsia, J., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27630 · Cited by 13
AKT1E17K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer
Malanga, D., Belmonte, S., Colelli, F., Scarfò, M., Marco, C. D., Oliveira, D. M., Mirante, T., Camastra, C., Gagliardi, M., Rizzuto, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147334 · Cited by 13
Metabolic Phenotypes, Dependencies, and Adaptation in Lung CancerPreprint
DeNicola, G. M., & Shackelford, D. B. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037838 · Cited by 13
Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review
Qiang, Z., Wan, J., Chen, X., & Wang, H. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-837 · Cited by 14
Expression of CHPF modulates cell proliferation and invasion in lung cancer
Cao, C., Liu, Y., Wang, Q., Zhao, J., Shi, M., & Zheng, J.-N. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209021 · Cited by 12
EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice
Higo, H., Ohashi, K., Makimoto, G., Nishii, K., Kudo, K., Kayatani, H., Watanabe, H., Kano, H., Ninomiya, K., Hotta, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.019 · Cited by 15
Translational Therapeutics in Genetically Engineered Mouse Models of CancerPreprint
Olive, K. P., & Politi, K. A. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069997 · Cited by 13
Self-citation
Validating cancer drug targets through chemical genetics
Burkard, M. E., & Jallepalli, P. V. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.08.002 · Cited by 11
An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1
Aftab, F., Rodriguez-Fuguet, A., Silva, L., Kobayashi, I. S., Sun, J., Politi, K. A., Levantini, E., Zhang, W., Kobayashi, S. S., & Zhang, W. C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02196-z · Cited by 11
Self-citation
Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
Xie, Z., Gu, Y., Lin, X., Ouyang, M., Qin, Y., Zhang, J., Liu, J., Mai, S., & Zhou, C. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1617561 · Cited by 11
IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins
Wang, R., Ni, C., Lou, X., Zhang, L., Wang, L., Yao, X., Duan, X., Wan, J., Li, P., & Qin, Z. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78248 · Cited by 10
MET Activation in Lung Cancer and Response to Targeted Therapies
Okun, S. A., Lu, D., Sew, K., Subramaniam, A., & Lockwood, W. W. (2025) · Cancers · doi:10.3390/cancers17020281 · Cited by 10
Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma
Zheng, M., Lin, Y., Kuo, Y., Lin, Y., Kuo, M.-H., Huang, T.-W., Shieh, Y., Huang, Y., & Chou, Y. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00910-z · Cited by 10
PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
Wang, S., Su, D., Chen, H., Lai, J.-C., Tang, C., Yu, L., Wang, Y., Yang, Y., Qin, M., Jia, L., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01317-2 · Cited by 10
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.
Yagui‐Beltrán, A., & Jablons, D. M. (2009) · PubMed · Cited by 10
C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
Jacobsen, B. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.621 · Cited by 10
Moving Towards Molecular-Guided Treatments: Erlotinib and Clinical Outcomes in Non-Small-Cell Lung Cancer Patients
Santarpía, M., Pas, T. M. D., Altavilla, G., Spaggiari, L., & Rosell, R. (2013) · Future Oncology · doi:10.2217/fon.13.6 · Cited by 11
Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations
Lin, C., & Yang, J. C. (2010) · Drugs · doi:10.2165/11587560-000000000-00000 · Cited by 10
EGFR Mutant Lung Cancer
Gong, Y., & Pao, W. J. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_171 · Cited by 10
Self-citation
Cellular Origins and Lineage Plasticity in CancerPreprint
Pitarresi, J. R., & Stanger, B. Z. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041389 · Cited by 10
Preclinical Models for Functional Precision Lung Cancer Research
Zeng, J., Kiss, Z., Ma, W., Liang, R., & Li, T. (2024) · Cancers · doi:10.3390/cancers17010022 · Cited by 10
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer
Moiseyenko, F. V., Kuligina, E. S., Жабина, А. С., Belukhin, S. A., Laidus, T. A., Martianov, A. S., Zagorodnev, K. A., Николаевна, С. Т., Chuinyshena, S. A., Kholmatov, M. M., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02128-6 · Cited by 11
Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
Nie, L., Wang, Y., Hsu, J.-M., Hou, J., Chu, Y., Chan, L.-C., Huo, L., Wei, Y., Deng, R., Tang, J., et al. (2023) · PubMed Central · Cited by 8
Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer
Jones, R. A., Franks, S. E., & Moorehead, R. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206948 · Cited by 8
Enhanced gefitinib‐induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia‐mutated kinase inhibition in non‐small‐cell lung cancer cells
Misumi, K., Sun, J., Kinomura, A., Miyata, Y., Okada, M., & Tashiro, S. (2016) · Cancer Science · doi:10.1111/cas.12899 · Cited by 9
HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1
Kumagai, T., Tomita, Y., Nakatsuka, S., Kimura, M., Kunimasa, K., Inoue, T., Tamiya, M., Nishino, K., Susaki, Y., Kusu, T., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12609 · Cited by 9
Different Epidermal Growth Factor Receptor Gene Mutations in a Patient with 2 Synchronous Lung Cancers
Nakano, H., Soda, H., Nakamura, Y., Uchida, K., Takasu, M., Nakatomi, K., Izumikawa, K., Hayashi, T., Nagayasu, T., Tsukamoto, K., et al. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.n.043 · Cited by 9
De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
Fujiwara, T., Kobayashi, T., Yasuma, T., D’Alessandro‐Gabazza, C. N., Toda, M., Fujimoto, H., Fujiwara, K., Takeshita, A., Nishihama, K., Okano, T., et al. (2020) · Cancers · doi:10.3390/cancers12103074 · Cited by 8
Clinical Applications of Kinase Inhibitors in Solid Tumors
Pao, W. J., & Girard, N. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00082-6 · Cited by 7
Self-citation
Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation
Yuan, P., Huang, S., Bao, F., Cao, J.-L., Sheng, H., Shi, L., Lv, W., & Hu, J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.024 · Cited by 8
Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question: Figure 1.Preprint
Haigis, K. M., Wistuba, I. I., & Kurie, J. M. (2007) · Genes & Development · doi:10.1101/gad.1532107 · Cited by 8
DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling
Lin, H.-H., Chang, C., Liao, Y., Yeh, S., Lin, H.-P. P., Ho, H., Cheung, C. H. Y., Juan, H., Chen, Y., Su, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02038-8 · Cited by 8
Application of proteomics in the study of rodent models of cancer
Terp, M. G., & Ditzel, H. J. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201300084 · Cited by 7
Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response
Kamath, A., Joseph, A. M., Gupta, K., Behera, D., Jaiswal, A., Dewan, R. K., & Rajala, M. S. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0010-5 · Cited by 7
Mouse models of triple negative [basal-like/claudin low] breast cancer
Herschkowitz, J. I., & Lubet, R. (2011) · Breast Disease · doi:10.3233/bd-2010-0321 · Cited by 7
Genetically Engineered Mouse Models for Human Lung Cancer
Inoue, K., Fry, E. A., Maglic, D., & Zhu, S. (2013) · InTech eBooks · doi:10.5772/53721 · Cited by 8
The National Cancer Institute’s PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets
Shoemaker, R. H., Suen, C. S., Holmes, C. A., Fay, J. R., & Steele, V. E. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.008 · Cited by 7
Targeted Therapies for Thymic Malignancies
Girard, N. (2010) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2010.08.004 · Cited by 7
Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy
Milella, M., Ciuffreda, L., & Bria, E. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_2 · Cited by 7
Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor resistance in lung cancer cells
Rai, K., Takigawa, N., Ito, S., Kashihara, H., Ichihara, E., Yasuda, T., Shimizu, K., Tanimoto, M., & Kiura, K. (2012) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.124.207 · Cited by 7
Genetic Mouse Models of Cancer
Winslow, M. M., & Jacks, T. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00009-3 · Cited by 7
The Evolution of Mouse Models of Cancer: Past, Present, and FuturePreprint
Abate-Shen, C. T., & Politi, K. A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041736 · Cited by 7
Self-citation
An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR‐Addicted Lung Tumorigenesis
Mokhtari, R. B., Sampath, D., Eversole, P., Lin, M. O. Y., Bosykh, D. A., Boopathy, G. T. K., Sivakumar, A., Wang, C., Kumar, R., Sheng, J. Y. P., et al. (2025) · Advanced Science · doi:10.1002/advs.202413443 · Cited by 8
Why Do Cancer Cells Become “Addicted” to Oncogenic Epidermal Growth Factor Receptor?
Mellinghoff, I. K. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040321 · Cited by 6
High expression of MCM10 is predictive of poor outcomes in lung adenocarcinoma
Shao, M., Yang, S., & Dong, S. (2021) · PeerJ · doi:10.7717/peerj.10560 · Cited by 6
Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention
Pan, J., Xiong, D., Zhang, Q., Palen, K. A., Shoemaker, R. H., Johnson, B. D., Sei, S., Wang, Y., & You, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1036563 · Cited by 6
Sensitivity and resistance to EGF-R inhibitors
Peipp, M., Dechant, M., & Valerius, T. (2009) · mAbs · doi:10.4161/mabs.1.6.10051 · Cited by 6
[Advances of the correlation between JAK-STAT3 signaling pathway and the biological behavior of non-small cell lung cancer].
Yu, Y., & Wang, Z. (2010) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2010.02.16 · Cited by 6
Omics technologies in diagnostics of lung adenocarcinoma
Novikova, S. E., Kurbatov, L. K., Zavialova, M. G., Zgoda, V. G., & Archakov, A. I. (2017) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20176303181 · Cited by 6
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
Karachaliou, N., & Rosell, R. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s50671 · Cited by 6
Pharmacogenetics in lung cancer for the lay doctor
Rosell, R., Vergnenégre, A., Fournel, P., Massutí, B., Camps, C., Isla, D., Sánchez, J. M., Morán, T., Sirera, R., & Tarón, M. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0083-8 · Cited by 5
Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma
Alikhanyan, K., Chen, Y., Kraut, S., & Sotillo, R. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.293 · Cited by 5
Genetically Modified Animal Models
Chaible, L. M., Kinoshita, D., Corat, M. A. F., & Dagli, M. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00027-9 · Cited by 5
Histological and proteomic analysis of reversible H-Ras V12G expression in transgenic mouse skin
Oh, W., Rishi, V., Pelech, S., & Vinson, C. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm127 · Cited by 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the MousePreprint
Vaishnavi, A., Kinsey, C. G., & McMahon, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041385 · Cited by 5
An agent-based modelling framework to study growth mechanisms in EGFR-L858R mutant cell alveolar type II cells
Coggan, H., Weeden, C. E., Pearce, P., Dalwadi, M. P., Magness, A. J., Swanton, C., & Page, K. M. (2024) · Royal Society Open Science · doi:10.1098/rsos.240413 · Cited by 4
The Development and Use of Genetically Tractable Preclinical Mouse Models
Hemann, M. T. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_23 · Cited by 5
Distinct characteristics of brain metastasis in lung adenocarcinoma: development of high-confidence cell lines
He, J., Tanei, Z., Wu, D.-S., Wang, L., Oda, Y., Tsuda, M., & Tanaka, S. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02038-4 · Cited by 3
Murine models of lung adenocarcinoma: Valuable tools for preclinical investigation
Shang, W., Lai, C., Luo, S., & Chen, L. (2025) · Gene · doi:10.1016/j.gene.2025.149802 · Cited by 3
Applications and Complementarity of Organ‐Chips and Animal Models in Lung Cancer Driver Gene Research
Wang, L., Wu, T., & Tsai, F. (2025) · Cell Biology International · doi:10.1002/cbin.70108 · Cited by 3
Pan-cancer macrophage atlas uncovers that MHC-IIhigh TAMs induce Treg activation through physical interactions
Yang, N., Yuan, H., Wang, W., Liu, X., Liu, C., Yao, Y., Li, Y., Gao, Y., Lin, X., Wang, M., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117230 · Cited by 3
Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib
Kiura, K., Takigawa, N., & Segawa, Y. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_21 · Cited by 3
Genetically Engineered Mouse Models in Preclinical Anti-Cancer Drug Development
Sergio, Y., & Melinda, G. (2011) · InTech eBooks · doi:10.5772/30666 · Cited by 3
Theme: Oncology - Molecular Mechanisms Determining the Efficacy of EGF Receptor-specific Tyrosine Kinase Inhibitors help to Identify Biomarker Candidates
Yamauchi, M., & Gotoh, N. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.9 · Cited by 3
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress
Costa, D. B. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.04.013 · Cited by 3
Age-Related Genetic Abnormalities: The Achilles‘ Heel for Customizing Therapy in Elderly Lung Cancer Patients
Rosell, R., Santarpía, M., Morán, T., Salazar, M., Kaen, D. L., & Ramírez, J. L. (2007) · Personalized Medicine · doi:10.2217/17410541.4.1.59 · Cited by 3
The Respiratory Tract
Braun, A. C., Ernst, H., Schaudien, D., Hoymann, H.-G., & Rittinghausen, S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382008-2.00012-x · Cited by 3
Genetically Modified Animal Models
Chaible, L. M., Kinoshita, D., Corat, M. A. F., & Dagli, M. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00033-6 · Cited by 3
Vitamin D and Lung Cancer
Shaurova, T., Seshadri, M., & Hershberger, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809963-6.00101-2 · Cited by 3
Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology
Sakashita, S., Shiba‐Ishii, A., Murata, Y., Sekimoto, R., Minami, Y., Sato, Y., & Noguchi, M. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.05.016 · Cited by 3
Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation
Song, Y., Wang, Y., Guan, A., Xue, J., Li, B., Huang, Z., Zheng, Z., Liang, N., Yang, Y., & Li, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1132940 · Cited by 3
Studying the immune landscape in lung cancer models: choosing the right experimental tools
Weeden, C. E., Ah-Cann, C., & Asselin-Labat, M.-L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.05 · Cited by 3
How CRISPR Is Revolutionizing the Generation of New Models for Cancer ResearchPreprint
Rivera, F. J. S., & Dow, L. E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041384 · Cited by 4
Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticityPreprint
Zhang, L., Chinnam, M., Balk, B., Zhang, X., Wang, Y., Shaurova, T., Alam, S., Pokharel, S., Singh, P., Jacobi, J. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.668485 · Cited by 3
Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations
Kalyanaraman, K. J., Corey, Z., Navarro, A., Heasley, L. E., & Nemenoff, R. A. (2025) · Cancers · doi:10.3390/cancers17152424 · Cited by 2
Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer
El‐Gazzar, A., Aschenbrenner, B., Forsthuber, A., Kramer, M., Kargarpour, Z., Metekol, S., John, L., Papaporfyriou, A., Bereš, M., Trouvilliez, S., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218448 · Cited by 2
Personalized treatment options in Non-small Cell Lung Cancer
PEHLIVANOGLU, S., Görgişen, G., Özeş, D., & Özeş, O. N. (2014) · Receptors & Clinical Investigation · doi:10.14800/rci.152 · Cited by 2
Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
Robles-Oteíza, C., Ayeni, D. O., Levy, S., Homer, R., Kaech, S. M., & Politi, K. A. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049072 · Cited by 2
Self-citation
Molecular Basis of Lung Cancer
Larsen, J. E., Govindan, R., & Minna, J. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00032-9 · Cited by 2
The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression
Danish, Q., Mokhdomi, T. A., Bukhari, S., & Ahmad, R. (2015) · Cancer Biomarkers · doi:10.3233/cbm-150502 · Cited by 2
Risk factors of brain metastasis of lung squamous cell carcinoma: a retrospective analysis of 188 patients from single center
Li, B., Liu, Y., Liu, S., Gu, X.-N., & Qiu, X. (2017) · Chinese Neurosurgical Journal · doi:10.1186/s41016-017-0096-1 · Cited by 2

Authors: Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Politi, Katerina
Zakowski, Maureen F.
Fan, Pang-Dian
Schonfeld, Emily A.
Pao, William
Varmus, Harold E.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2006-05-16
Volume: 20
Issue: 11
Pages: 1496-1510
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1417406
OpenAlex: W2126181231
Cited by: 478
References: 50
Citations by year: 2026: 10 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 9 · 2018: 24 · 2017: 11 · 2016: 23 · 2015: 38 · 2014: 25 · 2013: 19 · 2012: 27
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Funders: Memorial Sloan-Kettering Cancer Center
Dana-Farber Cancer Institute
University of Cincinnati
National Institutes of Health (R24 CA83084)
Genentech
National Cancer Institute (K08CA097980, R24CA083084)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: lung adenocarcinoma, epidermal growth factor receptor, EGFR mutation, exon 19 deletion, L858R mutation, tyrosine kinase inhibitors, erlotinib, gefitinib, transgenic mouse model, alveolar type II cells, tumor regression, tumor maintenance, doxycycline-inducible expression, bronchioloalveolar carcinoma
MeSH terms: Adenocarcinoma, Animals, Base Sequence, Humans, Lung Neoplasms, Magnetic Resonance Imaging, Phosphorylation, Protein-Tyrosine Kinases, Down-Regulation, DNA Primers, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks